By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic Nonsquamous NSCLC Key Points: The KEYNOTE-789 trial did not
By: Dr. Anam Kamal Ascension Providence Hospital; Michigan The standard of care for such patients is platinum-based doublet chemotherapy. In May 2021, the FDA granted accelerated approval to Amivantamab for the treatment
More
By Dr. Kanak Parmer Texas Tech University Health Sciences Center On October 16,2023 the U.S. Food and Drug Administration approved pembrolizumab for patients with resectable non-small cell lung cancer (NSCLC) tumors
More
MARIPOSA-2: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)- Mutated Locally Advanced or Metastatic Non- Small Cell
More
By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable
More
ESMO 2023 Update – KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology
More
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung Cancer Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck
More
ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology University of
More
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic,
More
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic Nonsquamous NSCLC Key Points: The KEYNOTE-789 trial did not
More
Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 LBA9005 Tumor Treating Field (TTFields) therapy with standard of care (SOC) in
More